IL6 and cancer: The overexpression of IL6 and the cancer stemness markers CD44 and ALDH1A1 was associated with poor survival in HNSCC patients, suggesting that the metformin-mediated interference with the IL6-stat3 axis that inhibited SASP-induced stemness might improve the survival of HNSCC patients.